TrialsgrambetaRCTs are beautiful

OCEANIC-AF

2025

Oral Factor XIa Inhibitor Asundexian versus Apixaban in Patients With Atrial Fibrillation

In 14,810 patients with atrial fibrillation at high stroke risk, asundexian was inferior for prevention of stroke or systemic embolism compared with apixaban.

Result

Efficacy: Stroke or systemic embolismHR 3.79 (95% CI 2.46-5.83)

Safety: Major bleedingHR 0.32 (95% CI 0.18-0.55)

Below 1 favours asundexian, above 1 favours apixaban.

Event rates Asundexian 1.3% vs apixaban 0.4% (stroke or systemic embolism)

Also reported: Asundexian inferior to apixaban. Trial stopped early.

Original publication
Subtopic
factor XIa inhibitor
Design
Phase 3 double-blind double-dummy active-controlled RCT, stopped early for inferiority
Relevance
Supporting: context rather than must-know.
Source
Piccini JP, et al. N Engl J Med. 2025;392(1):23-32.doi 10.1056/NEJMoa2407105

Discussion & critique

Possible underdosing of asundexian may have contributed to inferior efficacy, leaving the factor XIa hypothesis unresolved. Halted development of asundexian for stroke prevention in AF.

Discussed in podcasts